INT211969

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2007
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 34
Total Number 34
Disease Relevance 14.92
Pain Relevance 1.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Best1) plasma membrane (Best1)
Anatomy Link Frequency
hip 4
spine 3
neck 2
uterus 2
tibia 1
Best1 (Mus musculus)
Pain Link Frequency Relevance Heat
fibrosis 64 98.52 Very High Very High Very High
Pain 111 98.40 Very High Very High Very High
imagery 13 95.28 Very High Very High Very High
Lasting pain 10 94.88 High High
Inflammation 42 85.44 High High
withdrawal 9 83.84 Quite High
Central nervous system 19 76.36 Quite High
Bile 8 68.56 Quite High
cINOD 11 50.36 Quite High
backache 15 43.32 Quite Low
Disease Link Frequency Relevance Heat
Compression Fractures 10 99.88 Very High Very High Very High
Menopausal Vasomotor Symptoms 44 99.84 Very High Very High Very High
Osteoporosis 610 99.28 Very High Very High Very High
Osteogenesis Imperfecta 264 99.28 Very High Very High Very High
Celiac Disease 48 99.02 Very High Very High Very High
Cerebral Palsy 40 98.76 Very High Very High Very High
Bone Fracture 74 98.60 Very High Very High Very High
Cystic Fibrosis 64 98.52 Very High Very High Very High
Pain 105 98.40 Very High Very High Very High
Frailty 84 98.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Although a commendable effort was made in the SOTI trial to correct the BMD data for the atomic number effect of strontium, there is clearly a considerable uncertainty about the accuracy of the corrections that have been done.21,23 Furthermore a strong relationship between the increase in BMD and a subsequent reduction of a new vertebral or hip fracture risk has been demonstrated in SR-treated patients, indicating that BMD level monitoring may be valuable in these patients.
Positive_regulation (increase) of BMD in hip associated with frailty
1) Confidence 0.11 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971725 Disease Relevance 0.10 Pain Relevance 0.04
In the STRATOS study, the annual increase in lumbar BMD in the 2 g per day group (+7.3% per year) was significantly higher than in the placebo group (P < 0.001).
Positive_regulation (increase) of BMD
2) Confidence 0.11 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971725 Disease Relevance 0.15 Pain Relevance 0
Over a period of three years, in the SR group a baseline of 12.7% increase in BMD was observed in the lumbar spine, 7.2% in the femoral neck, and 8.6% in the total hip (P < 0.001 for all three comparisons with baseline values).21
Positive_regulation (increase) of BMD in neck
3) Confidence 0.11 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971725 Disease Relevance 0.25 Pain Relevance 0
However, when the DXA scanner software calculates BMD from measured X-ray transmission factors, the increased attenuation caused by bone strontium content (BSC) is considered as calcium content attenuation and this can lead to an artificial increase in BMD.
Positive_regulation (increase) of BMD
4) Confidence 0.11 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971725 Disease Relevance 0.13 Pain Relevance 0.03
In TROPOS, at three years in the SR group a 5.7% baseline percentage increment in BMD was observed at the femoral neck and 7.1% at the total hip (P = 0.001), compared with the placebo group.22
Positive_regulation (increment) of BMD in neck
5) Confidence 0.08 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971725 Disease Relevance 0.24 Pain Relevance 0
At 1 year in the Z-FAST study immediate zoledronic acid (n = 301) provided significant mean increases in lumbar spine and total hip BMD (p < 0.0001 for both) compared with delayed treatment (n = 301).23 Among patients in the delayed group, 8.3% met the requirement for zoledronic acid treatment at 12 months.
Positive_regulation (increases) of BMD in hip
6) Confidence 0.07 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2690973 Disease Relevance 0 Pain Relevance 0
GEN appeared to be associated with an increase in total BMD, cortical thickness, and cortical density by the time of the last pQCT scan in O + G versus OVX mice.
Positive_regulation (increase) of BMD
7) Confidence 0.05 Published 2010 Journal Journal of Osteoporosis Section Body Doc Link PMC2951124 Disease Relevance 0.15 Pain Relevance 0
At both 24 and 36 months, lumbar spine and total hip BMD continued to increase in the immediate zoledronic acid group, whereas BMD continued to decrease further in the delayed-treatment group.22 In the ZO-FAST, study lumbar spine BMD increased from baseline in the immediate group and decreased from baseline in the delayed group.
Positive_regulation (increased) of BMD in spine
8) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2690973 Disease Relevance 0 Pain Relevance 0
At a fixed BMD (?
Positive_regulation (fixed) of BMD
9) Confidence 0.04 Published 2008 Journal Osteoporos Int Section Body Doc Link PMC2267485 Disease Relevance 0.66 Pain Relevance 0
For example, the hip fracture probability ratio (women/men) with glucocorticoid use was 1.8 in the absence of BMD but 0.9 at a T-score of ?
Positive_regulation (absence) of BMD in hip associated with bone fracture
10) Confidence 0.04 Published 2008 Journal Osteoporos Int Section Body Doc Link PMC2267485 Disease Relevance 0.51 Pain Relevance 0
A CT based method for the measurement of BMD at the proximal humerus will be validated, and subsequently used to preoperatively determine BMD for the contralateral limb [37].
Spec (determine) Positive_regulation (determine) of BMD in limb
11) Confidence 0.02 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2992478 Disease Relevance 0.22 Pain Relevance 0.27
After 2 years, all bazedoxifene/CE regimens were associated with greater increases in lumbar BMD (range, 1.15%–2.61%) compared with placebo (–1.92%).
Positive_regulation (increases) of BMD
12) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.55 Pain Relevance 0.14
Moreover, in phase III clinical trials of postmenopausal women this compound, at doses ranging from 20 to 60 mg/day, demonstrated beneficial skeletal effects increasing BMD and preventing the occurrence of vertebral fractures compared to placebo, and with a similar efficacy than raloxifene.
Positive_regulation (increasing) of BMD
13) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.21 Pain Relevance 0
Importantly, among women within 5 years postmenopause, the mean increase from baseline in lumbar spine BMD at 2 years was significantly greater with all bazedoxifene/CE doses (range, 1.15%–2.61%) compared with raloxifene (0.15%; p < 0.05) (Figure 3a and b).
Positive_regulation (increase) of BMD in spine
14) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.51 Pain Relevance 0.13
Many studies indicated that the risk of fragility fractures increases progressively as BMD declines (Cummings et al 1990; Cummings et al 1993; Black et al 1992; Hui et al 1995).
Positive_regulation (increases) of BMD
15) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.89 Pain Relevance 0
The rationale for selecting bazedoxifene as the SERM in this combination is that it may offset estrogen stimulation of endometrial and breast tissue, without the necessity of using a progestin in women with an intact uterus or aggravating menopausal vasomotor symptoms, while stabilizing or increasing BMD (Gruber and Gruber 2004; Lewiecki 2007; Stump et al 2007).
Positive_regulation (increasing) of BMD in uterus associated with menopausal vasomotor symptoms
16) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.32 Pain Relevance 0
Among women >5 years postmenopause, the increase from baseline in lumbar spine BMD at 2 years was significantly greater with TSECs containing bazedoxifene 10 and 20 mg (range, 1.57%–2.42%) than with raloxifene (0.73%; p < 0.05).
Positive_regulation (increase) of BMD in spine
17) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.45 Pain Relevance 0.07
The histological quality of bone (assessed at the proximal tibia) was maintained and correlated well with the increases in BMD and compressive force data.
Positive_regulation (increases) of BMD in tibia
18) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.11 Pain Relevance 0.09
Indeed, treatment regimens with different compounds such bisphosphonates are known to produce a more pronounced increase in BMD when compared with all SERMs, including bazedoxifene (Liberman et al 1995; Hosking et al 1998; Ettinger et al 1999).
Positive_regulation (increase) of BMD
19) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.18 Pain Relevance 0
However, only women receiving bazedoxifene 40 mg experienced a significant increase from baseline in lumbar BMD at 6 and 12 months.
Positive_regulation (increase) of BMD
20) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643104 Disease Relevance 0.12 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox